Skip to main content
OpenTrials
Completed

NCT Number: NCT02488681

Micra Transcatheter Pacing System Continued Access Study Protocol

Medtronic is sponsoring the Micra Continued Access (CA) study to provide continued access to the Micra System while the marketing application is under review by the Food and Drug Administration (FDA).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bradycardia Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cedars-Sinai Medical Center, Los Angeles, California, United States

Loading trial locations.

About this study

The Micra CA study is a prospective, non-randomized, multi-center, study designed to allow controlled access of the Micra system when used as intended. All subjects enrolled in the Micra CA Study will be prospectively followed from implant, at 6-month intervals until study closure (i.e. FDA approval). Patients with previous or existing inactive implanted cardiac stimulation systems will have additional follow ups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
  • Subject meets Class I or ll indication for implantation of single chamber ventricular pacemaker and is intended to be implanted with a Micra System
  • Subject able and accessible for follow-up per study requirements
  • Subject is at least 18 years of age
  • Patient is not enrolled in a concurrent drug and/or device study that may confound registry result.

Exclusion criteria

  • Subject has had an acute myocardial infraction (AMI) within 30 days of implant
  • Subject has implantation of neurostimulator or any other chronically implanted device which uses current in the body
  • Subject with mechanical tricuspid valve, implanted vena cava filter, or left ventricular assist device (LVAD)
  • Subjects who are morbidly obese and physician believes telemetry communication of ≤5 inches (12.5 cm) could not be obtained with programmer head.
  • Subject who femoral venous anatomy is unable to accommodate a 23 French introducer sheath or implant on the right side of the heart (for example due to obstructions or sever tortuosity) in the opinion of the implanter
  • Subjects with known intolerance to Nickel-Titanium (Nitinol) Alloy
  • Subject for whom a single dose of 1.0mg dexamethasone acetate may be contraindicated
  • Subjects with life expectancy less than 12-months
  • Subject is enrolled in a concurrent drug and/or device study that may confound CA study results

Treatment and study plan

Micra Pacemaker Implant

Device

Primary outcomes

  1. Complications

    Time frame: 3 months post last follow up

    Micra system and/or procedure-related complication rate

Sponsors and collaborators

Lead sponsor

Medtronic

Industry

Registry information

Official study title

Medtronic Micra Transcatheter Pacing System Continued Access Study

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jul 2, 2015
Registry last updated
Apr 12, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.